Nucleic acid molecules
AssigneeCureVac AG
InventorsMariola FOTIN-MLECZEK, Katja FIEDLER, Aleksandra KOWALCZYK, Regina HEIDENREICH
Life of this patent
Estimating the term…
Loading patent…
AssigneeCureVac AG
InventorsMariola FOTIN-MLECZEK, Katja FIEDLER, Aleksandra KOWALCZYK, Regina HEIDENREICH
Estimating the term…
The present invention provides novel artificial nucleic acid molecules encoding at least one antigenic peptide or protein and at least one additional sequence preferably targeting the antigenic peptides or proteins to cellular compartments of interest. Further, the invention provides (pharmaceutical) compositions or vaccines and kits comprising said nucleic acid molecules. The nucleic acid molecules, (pharmaceutical) compositions or vaccines and kits are useful for treating a variety of diseases such as cancer, infectious diseases, autoimmune diseases, allergies or graft-versus host disease.
An artificial nucleic acid molecule comprising at least one coding region encoding
The artificial nucleic acid molecule according to any one of the preceding claims, wherein said at least one coding region further encodes
The artificial nucleic acid molecule according to any one of the preceding claims, wherein said at least one antigenic peptide or protein is selected from or derived from tumor antigens, viral, bacterial, protozoal, fungal or allogenic antigens.
The artificial nucleic acid molecule according to any one of the preceding claims wherein said IRSTepm comprises or consists of an amino acid sequence corresponding to any one of SEQ ID NOs:
The artificial nucleic acid molecule according to any one of the preceding claims, further encoding in its at least one coding region
The artificial nucleic acid molecule according to any one of the preceding claims, wherein said at least one coding region further encodes
The artificial nucleic acid molecule, preferably RNA, according to any one of the preceding claims, wherein the artificial nucleic acid molecule is mono-, bi-, or multicistronic.
The artificial nucleic acid molecule, preferably RNA, according to any one of the preceding claims, wherein said artificial nucleic acid molecule is modified, preferably stabilized.
The artificial nucleic acid molecule, preferably RNA, according to any one of the preceding claims, wherein
The artificial nucleic acid molecule, preferably RNA, according to any one of the preceding claims, which comprises a 5′-CAP structure, preferably m7GpppN or Cap1.
The artificial nucleic acid molecule, preferably RNA, according to any one of the preceding claims, which comprises at least one histone stem-loop.
The artificial nucleic acid molecule, preferably RNA, according to any one of the preceding claims, optionally comprising a poly(A) sequence, preferably comprising 10 to 200, 10 to 100, 40 to 80 or 50 to 70 adenosine nucleotides.
The artificial nucleic acid molecule, preferably RNA, according to any one of the preceding claims, optionally comprising a poly(C) sequence, preferably comprising 10 to 200, 10 to 100, 20 to 70, 20 to 60 or 10 to 40 cytosine nucleotides.
The artificial nucleic acid molecule, preferably RNA, according to any one of the preceding claims, which comprises, preferably in 5′ to 3′ direction, the following elements:
Dependencies are inferred from the claim text.